Clinical Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 14, 2285, April 15, 2008. doi: 10.1158/1078-0432.CCR-07-4102
© 2008 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tabone-Eglinger, S.
Right arrow Articles by Emile, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabone-Eglinger, S.
Right arrow Articles by Emile, J.-F.

Human Cancer Biology

KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors

Séverine Tabone-Eglinger1, Frédéric Subra5, Hiba El Sayadi1, Laurent Alberti1, Eric Tabone2, Jean-Philippe Michot2, Nathalie Théou-Anton4, Antoinette Lemoine4, Jean-Yves Blay1,3 and Jean-François Emile4,6,7

Authors' Affiliations: 1 Equipe Cytokines et Cancers, INSERM U590 and 2 Service d'Anatomie Pathologique, Centre Léon Bérard, 3 Université Claude Bernard Lyon 1 and Hôpital Edouard Herriot, Lyon, France, 4 INSERM U602, Hôpital Paul Brousse, Villejuif, France, 5 ENS Cachan, LBPA, UMR 8113, Cachan, France, 6 Hôpital Ambroise Paré APHP, Boulogne, France, and 7 PRES Universud and UVSQ, Versailles, France

Requests for reprints: Jean-Yves Blay, Centre Léon Bérard, Equipe Cytokines et Cancers, 28 rue Laënnec, 69373 Lyon cedex 08, France. Phone: 33-47878-7138; Fax: 33-47878-2720; E-mail: blay{at}lyon.fnclcc.fr.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Gastrointestinal stromal tumors (GIST) are frequently associated with gain-of-function mutations of KIT, which can be inhibited by imatinib both in vitro and in vivo. The survival of patients with GIST, following imatinib therapy, has been correlated with the nature of mutations but not with KIT expression.

Experimental Design: Subcellular localization, activation, and trafficking of the mature and the immature forms of KIT were investigated in GIST samples and in NIH3T3 cells infected with two different GIST-type exon 11–mutated human KIT cDNA.

Results: Paranuclear dot expression of KIT was more frequent in GISTs with homozygous KIT mutations than in those with heterozygous (P = 0.01) or no mutations (P < 0.01). Activation of the immature 125 kDa form of KIT was detected in most GISTs with KIT mutations but not in GISTs without KIT mutations. In NIH3T3 cells, mutant KIT was mainly retained within endoplasmic reticulum and Golgi compartments in an immature constitutively phosphorylated form, whereas the wild-type KIT was expressed at the plasma membrane, in a mature nonphosphorylated form. Imatinib-induced inhibition of the phosphorylation of immature and mature mutant KIT proteins resulted in the restoration of KIT expression at the cell surface.

Conclusions: These results show that GIST-type KIT mutations induce an activation-dependent alteration of normal maturation and trafficking, resulting in the intracellular retention of the activated kinase within the cell. These observations likely account for the absence of correlation between response to imatinib and KIT expression using immunohistochemistry and may deserve to be investigated in other tyrosine kinase–activated tumors.

Gastrointestinal stromal tumors (GIST) are the most frequent sarcomas of the digestive tract and express KIT protein in >95% of cases (1). Gain-of-function mutations in the KIT gene, and more recently, in the PDGFRA gene, have been shown to play a critical oncogenic role in GISTs (2–4). Imatinib mesylate, a KIT and PDGFR tyrosine kinase inhibitor, blocks the activation of both receptors in vitro and induces tumor control in >90% of patients with GIST (5–8). More than 80% of KIT mutations occur in exon 11 with a hotspot in the 550 to 561 codon region, whereas mutations in exon 9 and in exons 13 to 17 are observed in 10% to 15% and <1% of metastatic tumors, respectively (5, 9–13). Correlations between the nature of mutation (exon 11 versus others and sites of mutations within exon 11) and disease outcome prior to imatinib therapy has been reported in some but not all studies (9–12, 14–20). Conversely, response to imatinib therapy has consistently been influenced by the nature of KIT mutations: patients with exon 11 mutations were reported to have a better survival with imatinib than exon 9 or wild-type (WT) forms (5, 6). Of note, deletions involving the distal part of KIT exon 11 may be less favorable for response to imatinib (21). An intriguing observation is that immunohistochemical expression of the KIT protein in KIT-positive GISTs is not correlated with imatinib activity in vivo (22), in contrast with observations in other models such as HER2 amplification in breast cancer (23).

In the present work, we observed that KIT mutations result in the modification of the protein subcellular localization. In GISTs, as well as in NIH3T3-infected cells, mutated forms of KIT were mainly expressed in an immature phosphorylated-activated form within the intracellular compartments and with limited expression at the cell surface in this model. Activation of the immature form of KIT was only detectable in cells expressing exon 11 KIT juxtamembrane mutations; imatinib-induced blockade of the activation of the immature KIT form restored the expression of the mature form at the cell surface.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Reagents and antibodies. Recombinant human SCF (rhSCF) used for the assays was purchased from R&D Systems. Chinese hamster ovary-KL, used for the culture, was a kind gift from P. Dubreuil (UMR 599, Centre de Research en Cancérologie, Marseille, France). Imatinib mesylate was kindly provided by Novartis. The rabbit polyclonal anti-KIT antibody (A4502), used for immunochemistry and Western blot, and the phycoerythrin-conjugated mouse monoclonal anti-KIT antibody (clone 1045D2) used for flow cytometry analysis were from Dako. The antiphosphotyrosine 823 of KIT (pY823KIT) and the antiphosphotyrosine 703 of KIT (pY703KIT), used for Western blot and immunocytofluorescence analysis, were purchased from Clinisciences. For immunohistochemistry assays, CD34 (clone QBEND mouse) was purchased from Immunotech, and anti-S100 protein (polyclonal rabbit) was from Dako. Anti–β-actin antibody (Sigma-Aldrich) and secondary horseradish peroxidase antibodies (Dako) were used in Western blotting experiments, whereas rabbit anti-calnexin, mouse anti-Golgin58K (Abcam), anti-rabbit biotin (Dako), streptavidin-Alexa 594, anti-rabbit Alexa 647, and anti-mouse IGG1 Alexa 647 (Molecular Probes/Invitrogen) were used for immunofluorescence analysis.

Analysis of human GIST samples. The records of patients with GIST were retrieved from the files of Ambroise Paré University Hospital. Histology and immunohistochemistry of all cases were reviewed. Clinical records were reviewed as well, and no patients had received imatinib before surgical resection of the tumor. All the human samples were obtained by surgical resection done for therapeutic purposes and according to French ethical guidelines.

Mutations within exons 9, 11, 13, and 17 of KIT and within exons 12 and 18 of PDGFRA were detected as previously described (10, 24). Briefly, tumor DNA was extracted from either frozen or paraffin tumor samples after morphologic control. Screening of insertions and deletions within exons 9 and 11 of KIT and within exons 12 and 18 of PDGFRA was done by length analysis of PCR products (25), which allows the quantification of the mutant/wild-type ratio, and all samples were subjected to direct sequencing. Deletions or insertions within KIT exons 11 and 9 were considered as homozygous, when the fluorescence intensity of the mutant allele was at least three times higher than that of the wild-type allele. In all cases, histology confirmed that the analyzed sample contained >90% of tumor cells.

Immunohistochemistry was done on 4-µm-thick slides of paraffin-embedded GIST samples with anti-CD117 (1/300), anti-CD34 (1/2), and anti-S100 (1/200) antibodies. Slides were immersed for 20 min in a boiling antigen retrieval citrate buffer (pH 6), and staining was revealed with LSAB2 KIT (Dako). The cellular localization of KIT staining from 82 paraffin-embedded GIST samples was evaluated without knowledge of the mutational status.

Analysis of KIT expression and activation was done on 26 frozen GIST samples by Western blotting experiments. Samples were calibrated and mechanically homogenized (Mixer Mill MM 300) in lysis buffer (20 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L orthovanadate, 10 mmol/L NaF, 1 mmol/L PMSF, 0.5 µg/mL leupeptin, 1 µg/mL pepstatin, 10 IU/mL aprotinin, and 1% Triton X-100). Lysates were rocked for 30 min at 4°C, and then centrifuged to remove insoluble material. Supernatant protein contents were determined using Bradford solution. The normalized soluble proteins (supernatant fraction) were directly analyzed by SDS-PAGE Western blotting with anti-KIT, anti-pY703KIT, anti-pY823KIT, and anti–β-actin antibodies.

Production of recombinant viruses and NIH3T3 infection. The full-length human KIT cDNA (GNNK isoform), and two mutants (KITdel557-558 and KITdel564-581) were excised from the pGEM-Teasy plasmid through SalI and NotI restriction and inserted in oncoviral vectors pLNCX (Clontech) and MigR1 (26) for wild-type and mutant forms, respectively. Both retroviral vectors included the same cytomegalovirus promoter. To produce viral stocks, the plasmids pLNCX KIT-wt and MIGR KIT-mutants were independently cotransfectected with plasmid pMD.G (VSV.G envelope) and pBR322 containing inserts Gag-PolGpt into 293T cells using the standard calcium phosphate procedure. Briefly, 293T cells (2.5 x 106) were cotransfected with 15 µg of retroviral vector (pLNCX or MigR1), 10 µg of pBR322, and 5 µg of pMD.G for 12 h. The next day, the medium containing the virus was harvested. Titers of produced retroviral vectors were determined after infection on NIH3T3 cells and either resistance to geneticin (0.8-1 mg/mL) for pLNCX, either green fluorescent protein expression for MigR1 (the expression of green fluorescent protein is regulated by an internal ribosome entry sequence). Infection of NIH3T3 cells were done at a multiplicity of infection of 0.5. Cells with the pLNCX vector were selected with geneticin for 7 to 10 days (maintained for the culture) before being isolated and amplified. Cells with the MigR1 vector were amplified for 48 h after infection and green fluorescent protein–positive cells were sorted.

Cell culture. NIH3T3-infected cells were cultivated in DMEM with 10% newborn calf serum (Life Technologies), 2% penicillin/streptomycin, and 50 ng/mL of Chinese hamster ovary–mouse SCF so that the growth of wild-type and mutant forms were equivalent. Chinese hamster ovary–mouse SCF was removed during serum starvation for the assays.

To study proliferation in low serum concentrations, cells were plated at 50,000 cells per well, then starved for 4 h before incubation with DMEM containing 1% serum for the times indicated. At each time point, cells were harvested, suspended in a precise volume of medium, and then counted with a FACS scan (Becton Dickinson). Results were expressed as mean of triplicate ± SD.

To perform soft agar assays, cells were plated at 10,000 in 1 mL of 0.33% agar (Difco) in DMEM + 10% newborn calf serum with or without rhSCF, over a 0.5% 1 mL agar layer in triplicate in 35 mm dishes. After 3 weeks, plates were stained with 0.005% crystal violet and colonies were counted with Gene Tools software (Ozyme). Each condition was done in triplicate and results are given as the mean number of colonies.

mRNA analysis. The mRNA of NIH3T3 cells was extracted according to TRIzol method (Invitrogen). Then, 5 µg of RNA was submitted to reverse transcriptase (Super Script II, Invitrogen). Real-time PCR and subsequent calculations were done with the ABI Prism 7000 sequence detection system (Applied Biosystems).

Primers and probes were described previously (24). The PCR mixture contained 1x TaqMan Universal PCR Master Mix reagents (Applied Biosystems), 400 nmol/L of KIT forward and reverse primers, 200 nmol/L of probe, 0.25 µmol/L of amperase UNG, and 5 µg of KIT cDNA in a total volume of 50 µL. PCR conditions consisted of two steps of 5 min each at 55°C and 5 min at 95°C, followed by 50 cycles of 15 s at 95°C and 1 min at 60°C. TaqMan rRNA control reagents (Applied Biosystems), designed for ribosomal 18S RNA amplification, were used as references to normalize the results. Experiments were done in triplicate. Results were expressed as ratios of KIT to 18S PCR products (equivalency of the efficacy of the two PCRs was previously verified).

Protein analysis. NIH3T3 cells were grown to 80% confluence in complete medium, and then starved for 4 h before incubation with rhSCF or imatinib for the concentrations and times indicated. Cells were washed with cold PBS, and lysed directly in culture plates with 200 µL/10 cm2 of lysis solution [10 mmol/L TRIS (pH 7.4), 150 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L EDTA, 1 mmol/L sodium orthovanadate, 10 mmol/L NaF, 1 mmol/L PMSF, 0.5 µg/mL leupeptin, 1 µg/mL pepstatin A, and 10 IU/mL aprotinin] for 30 min at 4°C. The soluble protein (supernatant fraction) was either directly analyzed by SDS-PAGE Western blotting or first immunoprecipitated with the rabbit anti-KIT antibody.

For cell surface biotinylation of the protein, cells were labeled with Sulfo-NHS biotin (Perbio Science) according to the manufacturer's instructions before protein extraction, KIT immunoprecipitation, and Western blotting analysis.

Flow cytometry. NIH3T3 were grown to 80% confluence in complete DMEM, then serum-starved for 4 h before incubation or not with SCF or imatinib. Cells were then harvested and resuspended in cold PBS before incubation with a phycoerythrin–conjugated anti-KIT antibody (Dako) for 15 min at 4°C. Cells were analyzed by flow cytometry on a FACS Scan (Becton Dickinson) and analyzed with Cell Quest Pro Software (Becton Dickinson). Results were expressed as mean of fluorescence intensity.

For analysis of total cell expression of KIT, cells were fixed in 4% PBS-paraformaldehyde for 15 min at 4°C before permeabilization with 5% PBS-bovine serum albumin/0.3% saponin for 15 min at room temperature, and then incubated with the phycoerythrin-conjugated anti-KIT antibody.

To inhibit KIT internalization via disruption of lipid rafts, cholesterol depletion of cell membranes was done using methyl-β-cyclodextrin (Sigma-Aldrich). Cells were serum-starved for 30 min, then incubated for 30 min with 30 mmol/L of methyl-β-cyclodextrin in DMEM without serum, and finally stimulated or not by 100 ng/mL of rhSCF for 20 min before staining with phycoerythrin-conjugated anti-KIT antibody.

Immunocytochemistry and confocal microscopy in NIH3T3-infected cells. Immunocytochemistry of NIH3T3-infected cells was done on pellets previously embedded with Shandon Cytoblock Cell Preparation System (Thermo Scientific) according to the manufacturer's instructions. Dewaxed paraffin sections were stained with anti-KIT antibody (Dako,) and revealed by the Ultra View DAB Detection Kit (Ventana Medical System). Slides were observed at x100 original magnification with Axioskop microscope (Zeiss), and then representative photographs were taken using Nikon Cool Pix camera (Nikon).

For confocal microscopy, cells were cultivated for 24 h onto polylysin-coated slides before fixation with 4% paraformaldehyde in PBS. Cells were then permeabilized with 0.1% Triton X-100, then stained with either anti-KIT, anti-pY703KIT, or anti-pY823 (revealed with anti-rabbit biotin plus streptavidin-Alexa 594), and/or with either anti-Golgin58K (revealed with anti-mouse IGG1 Alexa 647) or with rabbit anti-calnexin (revealed with anti-rabbit Alexa 647). Before incubation with anti-calnexin antibody, KIT or pY703 staining was fixed and blocked to avoid cross-binding with the other anti-rabbit antibody. Slides were mounted with Vectashield Hard-Set containing 4',6-diamidino-2-phenylindole for nuclear staining (Vector Laboratories/AbCys). Representative photographs were taken at original magnification (x63) with a Leica microscope TCS SP2. Colocalization analyses were done with WCIF ImageJ software8 according to the approach of Costes et al. (27).

Statistical analysis. For proliferation assays, the mean triplicate counts were compared among the different infected cell types using Student's t test. All data are expressed as mean ± SD. The relevance of Golgi-like staining in GISTs was calculated with a {chi}2 test.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Perinuclear expression of KIT in GISTs. Cellular localization of KIT has previously been shown to be heterogeneous in GISTs, with either plasma membrane, diffuse cytoplasmic, and/or paranuclear dot-like patterns (i.e., "Golgi-like"). The slides of all GIST cases that were diagnosed with homozygous KIT mutations (n = 17) were compared with those of KIT-positive GISTs without KIT mutations (n = 14), and those of 51 GISTs with heterozygous KIT mutations (three times the number of cases with homozygous mutations, randomly chosen in our series; Table 1 ). We observed 11 of 51 point mutations, 3 of 51 insertions, and 37 of 51 deletions in the heterozygous group, and 16 of 17 exon 11 deletions (Fig. 1A ) and 1 of 17 exon 9 insertions in the homozygous group. KIT was expressed (Fig. 1B) in the cytoplasm of 14 cases (82%) with homozygous mutations, 10 cases (71%) without mutations, and 32 cases (63%) with heterozygous mutations. Plasma membrane expression of KIT was observed in 5 (29%), 9 (64%), and 31 (61%) cases from the same group, respectively, and was therefore significantly less frequent in the first group (P = 0.05, {chi}2 test). Paranuclear dot-like patterns were observed in 12 (70%), 2 (14%), and 18 (35%) cases (P < 0.01; {chi}2 test); therefore, predominantly in GISTs with homozygous mutations, as compared with wild-type GISTs and to GISTs with heterozygous mutations.


View this table:
[in this window]
[in a new window]

  		Table 1. Comparison of KIT subcellular staining in three subsets of patients with GIST

 

Figure 1
View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. KIT perinuclear expression in GISTs with homozygous mutations and phosphorylation of the immature KIT form in GIST protein extracts. A, wild-type (arrow; 270 bp) and mutant alleles of KIT were detected by length analysis for fluorescent PCR products. These five GISTs had deletions within exon 11 of KIT, three of which were considered as homozygous (cases Y04-108, Y04-109, and Y04-210) because of the low amount of wild-type as compared with mutant alleles. B, KIT immunohistochemical staining of GIST on paraffin-embedded samples (top) and NIH3T3 embedded cells (bottom) disclosed a predominant Golgi-like pattern in GISTs with homozygous KIT mutations or in NIH3T3 KIT D6–infected cells (right) and a membrane and/or cytoplasmic pattern in GISTs without mutations or NIH3T3 WT KIT–infected cells (left). Bar, 20 µmol/L. C, Western blot analysis of protein extracts of GIST frozen samples disclosed a variable KIT expression, with a main heavy (mature, 145 kDa) and a minor light (immature, 125 kDa) form. KIT phosphorylation (Tyr703 and Tyr823 residues) of both forms was analyzed in GISTs with heterozygous or homozygous KIT mutations and GISTs without mutations of KIT and PDGFRA. Protein extracts of wild-type NIH3T3– and D6–infected cells were analyzed in each blot as a control of KIT expression and phosphorylation. β-Actin expression was analyzed as a loading control.

 
The expression and activation of KIT extracted from GIST frozen samples was then analyzed using Western blot analyses. Samples from GISTs without deletions (n = 11), with heterozygous deletions (n = 12; two point mutations, three insertions, and six deletions in exon 11; one insertion in exon 9), or with homozygous deletions (n = 3) of KIT gene were compared. The mature (145 kDa) form of KIT was phosphorylated in most of the 26 tumor samples. Importantly, the immature (125 kDa) form of KIT was also phosphorylated in GISTs with KIT mutations, but not (pY823) or weakly (pY703) in GISTs with wild-type KIT (Fig. 1C).

Functional properties of NIH3T3 cells infected by human exon 11 KIT mutants or wild-type forms. To evaluate the significance of the abnormal pattern of expression and activation of KIT in KIT-mutated GISTs, murine fibroblast cell lines (NIH3T3) were stably infected with oncoviral vectors containing either wild-type KIT (WT), mutated KIT11 DelWK557-558 (D6), or mutated KIT11 Del NGNNYVYIDPTQPYDHK564-K581 (D54) human KIT cDNA, or with the empty vector (CT). The stably infected NIH3T3 cells, WT, D6, and D54 expressed the KIT protein in two forms: the mature and the immature proteins of 145 and the 125 kDa, respectively (Fig. 2A ). D6 and D54 were gain-of-function mutations. Indeed, KIT was constitutively activated in cells infected with D6 and D54 oncoviral vectors, as shown by the phosphorylation of the Tyr823 residue in these cells in the absence of rhSCF, whereas WT KIT activation was weak in this condition. Upon stimulation with rhSCF, WT KIT was highly phosphorylated and its expression was decreased (Fig. 2A).


Figure 2
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Characterization of the NIH3T3-infected cell lines. A, the infected NIH3T3 cell lines were incubated with or without 100 ng/mL of rhSCF for 20 min and the KIT protein expression and the phosphorylation of the Tyr823 residue were analyzed by Western blot. β-Actin expression was analyzed as loading control (CT, control; WT, wild-type KIT; D6, KIT D6; D54, KIT D54). B, the proliferation of control, wild-type, D6, and D54 NIH3T3 cell lines was compared. Cells were plated at 50,000 cells per well and then starved for 4 h before incubation with DMEM supplemented by 1% serum. After 36, 60, and 84 h of culture, the cells were harvested and counted. Points, mean of triplicate results; bars, SD. C, the capacity to grow in soft agar was tested for control, wild-type, D6, and D54 NIH3T3 cell lines. Cells were plated in 1 mL of 0.33% agar, over a 2 mL 0.5% agar layer. Four weeks later, the plates were stained and colonies were counted with Gene Tools software. Each experiment was done in triplicate. Columns, mean number of colonies per plate; bars, SD.

 
The oncogenic properties of KIT mutants were then compared (Fig. 2B): D6 and D54 mutants proliferated significantly more than wild-type or control NIH3T3 cells after 60 and 84 hours of culture in low serum concentrations (P < 0.05). We further tested the transforming potential of infected NIH3T3 cells by culturing them in soft agar (Fig. 2C; ref. 28). Only D6- and D54-infected NIH3T3 formed colonies in soft agar assays without the addition of rhSCF (mean[CT] = 1.00 ± 2.00; mean[WT] = 0.00 ± 0.00; mean[D6] = 45.92 ± 11.34; mean[54] = 29.00 ± 14.66).

Subcellular expression of KIT mutants and WT KIT in NIH3T3 cells. Using flow cytometry, the expression of KIT in D6, D54, and wild-type infected cells was observed at the cell membrane. In the absence of rhSCF, the WT KIT receptor was expressed at a high level. The constitutively activated D6 and D54 mutants were also detectable on cell surface, albeit at reduced levels as compared with the wild-type receptor (Fig. 3A ).


Figure 3
View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. KIT basal expression in NIH3T3-infected cells. A, membrane KIT expression without ligand stimulation in infected NIH3T3 cells lines was analyzed by flow cytometry. Histograms represent the number of cells as a function of the fluorescent intensity of KIT staining by a phycoerythrin-conjugated anti-KIT antibody. Means of fluorescence intensity (MFI) were compared. B, real-time PCR was used to quantify the expression level of KIT RNA in KIT-infected NIH3T3 cells lines (WT, D6, and D54). The noninfected NIH3T3 cells line (CT) was used for PCR-negative controls. Points, mean ratio of PCR products of KIT/18S RNA; bars, SD. C, flow cytometry analysis of permeabilized (thick black lines, KIT staining; dotted lines, isotype control staining) or non-permeabilized (thick gray lines, KIT staining; thin gray lines, isotype control) cells was done to compare total KIT or cell surface expression, respectively, in wild-type and D6-infected cells. The mean of fluorescence intensity was higher in D6 total expression than at the cell surface.

 
To get more insight into the mechanisms of reduced KIT protein expression in D6- and D54-infected cells (Figs. 2A and 3C), KIT mRNA expression was compared in infected cells (Fig. 3B) using real-time PCR quantification. KIT/18S RNA ratios were similar in wild-type and mutant infected cells (range, 0.38-0.47), and was significantly higher than in control cells (which were negative for KIT expression).

The overall expression (i.e., plasma membrane and intracellular) of KIT was then analyzed by flow cytometry following cellular permeabilization (Fig. 3C). Although no differences were observed between intact and permeabilized wild-type infected cells, the expression of mutant KIT protein was higher in permeabilized cells than at the cell surface. Moreover, similar to the observations made in samples from GISTs with homozygous KIT mutations, KIT immunochemical expression was predominantly found in the perinuclear region in NIH3T3 cells infected with the mutated KIT gene, whereas it remained predominantly at the plasma membrane and diffusely in the cytoplasm in wild-type cells (Fig. 1B).

SCF-dependent internalization and activation of KIT in wild-type but not in mutant-infected cells. The cell surface expression of WT KIT was significantly decreased when WT KIT–infected cells were stimulated for 24 hours by rhSCF; the inhibition of KIT activation by 1 µmol/L of imatinib mainly restored the membrane expression of KIT (Fig. 4A ). In constitutively activated KIT mutant–infected cells, additional stimulation with rhSCF did not significantly alter the membrane expression of the receptor stimulation. In contrast, the inhibition of KIT activation by imatinib, as shown further, was associated with an increased expression of the receptors at the cell surface (higher for D6 than for D54).


Figure 4
View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Regulation of KIT expression according to the kinase activity in the different infected cells. A, regulation of KIT cell surface expression after 24 h of stimulation by 100 ng/mL of rhSCF (SCF) and/or 1 µmol/L of imatinib (STI) was observed using flow cytometry in wild-type, D6, and D54 cells. B, effective KIT internalization was assessed using flow cytometry analysis of KIT cell surface expression with or without 30 mmol/L of methyl-β-cyclodextrin. Disruption of lipid raft for WT KIT–infected cells was followed or not by 20 min of stimulation with 100 ng/mL of rhSCF. Black arrows, modification of KIT expression under the effect of SCF with or without methyl-β-cyclodextrin.

 
Methyl-β-cyclodextrin has been shown to inhibit the lipid raft pathway of KIT receptor internalization (29). Although methyl-β-cyclodextrin dramatically reduced the rhSCF-induced internalization of WT KIT, it had no effects on the surface expression of mutant KIT proteins, indicating that the weak membrane expression of the mutated KIT proteins was not due to an increased internalization (Fig. 4B).

Specific phosphorylation of the immature form of the mutated KIT receptor. The 145 and 125 kDa forms of KIT differ by glycosylation patterns (30): the 145 kDa protein corresponds to the maturation of the 125 kDa form within the Golgi apparatus, and complete maturation is requested for plasma cell membrane targeting.

To investigate whether the immature 125 kDa form was not expressed at the plasma membrane, the surface proteins of infected NIH3T3 cells were biotinylated and detected with Western blotting analysis after immunoprecipitation of both immature and mature forms of KIT (Fig. 5A ): only the mature 145 kDa form was expressed at the cell surface, whereas the intracellular immature 125 kDa form of the mutated KIT, which was phosphorylated on the Tyr703 (data not shown) and the Tyr823 residues, was retained intracellularly.


Figure 5
View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. The immature form of KIT mutants were phosphorylated in the intracellular compartment. A, biotinylation of cell surface proteins was done on WT KIT–infected cells stimulated by 100 ng/mL of rhSCF for 20 min or on KIT D6–infected cells followed by KIT immunoprecipitation and Western blotting. The KIT expression, phosphorylation of the Tyr823 residue and the biotin binding, were analyzed to detect the intracellular localization and the phosphorylation of the immature form of KIT in D6 cells. B, confocal localization of KIT expression and activation. After permeabilization of infected WT KIT (stimulated for 15 min or not with rhSCF as indicated) and D6 NIH3T3 (inhibited for 1 h or not with imatinib) cell lines, the KIT protein and its phosphorylated form (pY703KIT) were revealed with the Alexa 594 fluorochrome (red). 4',6-Diamidino-2-phenylindole was used for nuclear coloration (blue). The phosphorylated form of KIT (p703KIT; red) was colocalized with endoplasmic reticulum marker (Calnexin) or Golgi marker (Golgin58K) revealed with Alexa 647 fluorochrome (magenta). Colocalizations were highlighted using contrasting colors (red for red and green for magenta) and whitening of most fluorescent colocalized points. Bars, 9 µmol/L. C, effect of 24-h stimulation with 100 ng/mL of rhSCF (SCF) or inhibition with 1 µmol/L of imatinib on the expression and the phosphorylation (Tyr703 and Tyr823 residues) of the immature (125 kDa) and mature (145 kDa) forms of KIT using Western blot analysis. β-Actin expression was analyzed as a loading control.

 
Confocal microscopy confirmed the intracellular localization of the mutant KIT (Fig. 5B). Indeed, phosphorylated Tyr703 (Fig. 5B) and Tyr823 (data not shown) of KIT mutants were colocalized with the endoplasmic reticulum (as shown by coexpression of the specific calnexin) and Golgi apparatus (as shown by the coexpression of the specific Golgin58K) compartments.

The relation between activation and expression of mature and immature forms of KIT in NIH3T3 cells was then investigated using Western blotting. Both mature and immature forms of mutant KIT were phosphorylated on Tyr703 or Tyr823 residues (Figs. 2A, 5A and C). Their stimulation by rhSCF did not alter mature or immature form of KIT expression (Fig. 5C). In contrast, prolonged inhibition of these mutants with 1 µmol/L of imatinib increased the expression of the mature form (Fig. 5C), and reduced the expression of the immature form, resulting in a pattern of KIT expression which is similar to unstimulated WT KIT. As we observed in the previous experiments, only the mature 145 kDa form of WT KIT was phosphorylated after rhSCF stimulation (Figs. 2A and 5A). Moreover, its activation was transient, as phosphorylation of Tyr703 and Tyr823 was weak after 24 hours of rhSCF stimulation (Fig. 5C). The prolonged stimulation also reduced the mature WT KIT form expression, but did not alter the expression of the immature form. Finally, the expression of the mature form was restored upon further addition of 1 µmol/L of imatinib (Fig. 5C).


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In the present work, we show that an immature form of GIST-type mutated KIT, but not of wild-type KIT, is activated and undergoes an abnormal subcellular trafficking in GISTs and in KIT-infected NIH3T3 cells.

In-frame deletions within exon 11 (especially codons 557-558) of KIT are present in more than half of GISTs (5, 9–13) and result in constitutive activation of KIT in these human tumors (3). Gain-of-function mutations are a major event in GIST oncogenesis, as shown by the high incidence of GISTs in patients with inherited KIT mutations (31–33), in transgenic mice (34, 35), and in studies reporting the major antitumor effects of treatments with the KIT inhibitor imatinib (8). Two forms of KIT protein are described in GISTs (4): the 125 kDa form is a precursor of the 145 kDa form (36) and lacks the complex glycosylation necessary for its cell surface targeting (30, 37). In accordance with the data reported in the literature, we found that KIT was activated in most of our GIST samples, as shown by phosphorylation of the mature (145 kDa) form of KIT. The results here further indicate that samples with homozygous KIT or heterozygous mutations on exon 11 (as well as one with exon 9), also presented an activation of the immature (125 kDa) form. These observations are consistent with the report of Duensing et al. who also observed the phosphorylation of the 125 kDa KIT form in some primary GISTs (38). Interestingly, in GISTs with KIT homozygous mutations, we observed a predominant paranuclear dot pattern of KIT on immunohistochemical staining, as compared with GISTs without mutations (P < 0.01) and those with heterozygous mutations (P = 0.01). Immunochemical features of KIT expression described in GISTs are variable: it can be diffuse or dot-like within the cytoplasm, as well as in the plasma membrane (22). The mechanisms underlying these observations were not known. Pauls et al. have observed that dot-like staining (also called "Golgi pattern") of KIT was very frequently associated with mutations within the KIT gene (39). To evaluate the significance of the abnormal pattern of KIT expression and activation in KIT-mutated GISTs, we further investigated the KIT expression and maturation in NIH3T3-infected cells expressing either the wild-type or the juxtamembrane-mutated forms of human KIT.

The results we obtained with the NIH3T3 fibroblasts infected with WT KIT oncoviral vector are consistent with other models published until now. As in GISTs, the two forms of KIT were detected in NIH3T3-infected cells. The mature form of WT KIT, infected in NIH3T3 cells, was predominant and mainly expressed at the cell surface. It activation with rhSCF resulted in the phosphorylation of the mature form but not the immature one. In fact, SCF stimulation of wild-type KIT receptor induces dimerization and activation of the mature (145 kDa) form but not of the immature (125 kDa) form (36). Moreover, previous studies have shown that the 125 kDa form is intracytoplasmic, retained within the endoplasmic reticulum or the Golgi compartments (30, 37). Finally, as already suggested by cholesterol depletion experiments (40), the internalization of the mature activated WT KIT form was shown to be lipid raft–dependent.

In contrast to the wild-type KIT, which was mainly expressed at the cell surface as a mature 145 kDa form, the mutated form was predominantly expressed within the endoplasmic reticulum and the Golgi compartments as the immature (125 kDa) form. As for GIST samples, activation of the immature form was exclusively detected in mutants. Several groups have also transfected murine cell lines with human KIT containing gain-of-function mutations. The 125 kDa form was either predominantly expressed (41, 42), as in the present study and in two others with deletion or mutation of codon 559, or was the only detected form as in two models with activating mutations of codon 816 (30, 37). Phosphorylation of the immature form in murine cell lines transfected by mutated but not wild-type alleles of KIT has also been observed by others (30, 42, 43). Debiec-Rychter et al. used cell lines transfected with a KIT mutant containing a deletion of codons 557 to 558, such as in the D6 model of the present work, but additionally associated with a mutation in exon 13 (T670I). They observed that the 125 kDa form was highly expressed and also slightly phosphorylated (44).

Several lines of evidence strongly suggest that the immature 125 kDa KIT protein plays an essential oncogenic role in NIH3T3 and in GIST, bypassing the normal posttranslational maturation and trafficking. First, the cell membrane expression of KIT was weaker in KIT mutant compared with WT KIT–infected cells, whereas KIT mRNA expression was similar in the two cases. This was not due to a higher internalization of the receptor induced by KIT autoactivation because assays of lipid raft disruption did not increase KIT expression at the cell surface. Furthermore, the immature 125 kDa form of KIT, although expressed under an activated form, was not found at the cell surface using a biotinylation assay. Finally, mutant KIT was predominantly expressed in the endoplasmic reticulum and Golgi compartments in an activated form using confocal microscopy. Using this model, we also showed that inhibition of KIT kinase activity with imatinib blocked mutant KIT phosphorylation, restored normal maturation of these proteins, and enabled its migration in the mature form to the cell surface, showing that abnormal maturation and trafficking of the mutated KIT protein was a result of its constitutive activation. Taken together, these data might suggest that activating mutations lead to a premature phosphorylation of KIT resulting in a premature regulation of the protein that decreases its cell surface expression. Furthermore, alteration of signaling pathways, often observed in GIST models (38, 43), might be a consequence of the endoplasmic reticulum/Golgi localization as it has been reported for the KIT kinase domain mutant (30) and needs to be further investigated.

Gain-of-function mutations of tyrosine kinase receptors have been shown to be major events in many human tumors (for review, see ref. 45). Here, we showed that gain-of-function mutations of KIT not only induced an autoactivation of the receptor, but also resulted in a blockade of normal KIT maturation and intracellular trafficking that resulted in an abnormal activation of its intracellular immature form. Similar results were recently published with the kinase domain mutant frequently found in mastocytosis, however, its relevance in the in vivo situation has not yet been shown (30). Moreover, abnormal maturation and trafficking of tyrosine kinase receptors has also been observed in other tyrosine kinase receptors such as CSFR1 (46) and Flt3, which have been related to its tyrosine kinase activity (47). Interestingly, we observed that the KIT inhibitor imatinib partially relieved this blockade and restored KIT expression at the cell surface, suggesting that the constitutional activation of mutated KIT is responsible for the intracellular retention of the protein. Moreover, we previously showed that SCF was detectable in most GISTs, and might therefore contribute to its activation (48). Several tyrosine kinase inhibitors are currently used to treat patients with cancer, and belong to two main types: antibodies directed against surface receptors and small specific inhibitors. The combination of both types of tyrosine kinase receptor inhibitors, as it has been suggested to target epidermal growth factor receptor in lung cancer (49, 50), may be active in both normal and bypass pathways.

These findings could have important implications in the understanding of the biology of mutant KIT receptor and for the selection of patients for targeted therapies. Mutant KIT receptor was activated within intracellular compartments of the cell, and thus, might escape the physiologic mechanisms of deactivation following ligand binding. Imatinib blocks this phenomenon, restoring normal cell membrane expression of a nonactivated immature form of the receptor. These observations may account for the lack of correlation between KIT expression at the cell surface and response to imatinib; their possible relevance to other tyrosine kinase receptors in different tumor models and tyrosine kinase inhibitor activities also needs to be explored. They also suggest that a cell-permeable inhibitor of KIT, such as imatinib, will likely be more efficient than a non–cell-permeable molecule. Whether these observations are relevant in other models of mutated activated tyrosine kinase receptors will need to be investigated.


   Acknowledgments
 
We thank A. Puisieux, C. Caux, C. Menetrier Caux, I. Puisieux, M. Gobert, I. Le Mercier, and all members of "Equipe Cytokines et Cancers" and INSERM U590 for fruitful discussions; as well as J. Valladeau and CCQ (confocal microscopy) and R. Saffroy (real-time PCR) for their technical advice.


   Footnotes
 
Grant support: S. Tabone-Eglinger is a fellow of ANRT, with financial support from Centre Léon Bérard Cancer and Novartis SA. J-Y. Blay and J-F. Emile received research grants from Novartis. Novartis also kindly provided imatinib mesylate. Association pour la Recherche sur le Cancer, CONTICANET, Network of Excellence FP6-018806, Ligue Contre le Cancer (Comité de l'Ain et Comité du Rhône), the Breast Cancer Research Foundation, Institut National du Cancer, Cancéropôle Lyon Auvergne Rhône Alpes, and BQR2007 Université Versailles SQY.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: J-Y. Blay and J-F. Emile contributed equally to this work.

8 http://www.uhnresearch.ca/wcif Back

Received 9/ 5/07; revised 11/ 5/07; accepted 11/ 5/07.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12.[CrossRef][Medline]
  2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708–10.[Abstract/Free Full Text]
  3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–80.[Abstract/Free Full Text]
  4. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118–21.[Abstract/Free Full Text]
  5. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689–95.[CrossRef][Medline]
  6. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9.[Abstract/Free Full Text]
  7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–6.[Free Full Text]
  8. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–3.[CrossRef][Medline]
  9. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006;130:1573–81.[CrossRef][Medline]
  10. Emile JF, Theou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004;2:597–605.[CrossRef][Medline]
  11. Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004;10:3076–81.[Abstract/Free Full Text]
  12. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190–8.[Abstract/Free Full Text]
  13. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477–89.[CrossRef][Medline]
  14. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329–37.[Abstract/Free Full Text]
  15. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003;34:1306–12.[CrossRef][Medline]
  16. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633–6.[Medline]
  17. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53–60.[Abstract/Free Full Text]
  18. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297–300.[Abstract/Free Full Text]
  19. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887–95.[CrossRef][Medline]
  20. Emile JF, Tabone-Eglinger S, Theou-Anton N, Lemoine A. Prognostic value of KIT exon 11 deletions in GISTs. Gastroenterology 2006;131:976–7.[CrossRef][Medline]
  21. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093–103.[CrossRef][Medline]
  22. Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007;38:679–87.[CrossRef][Medline]
  23. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003;9:5078–84.[Abstract/Free Full Text]
  24. Theou N, Tabone S, Saffroy R, et al. High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors. Biochim Biophys Acta 2004;1688:250–6.[Medline]
  25. Emile JF, Lemoine A, Bienfait N, et al. Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors. Diagn Mol Pathol 2002;11:107–12.[CrossRef][Medline]
  26. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780–92.[Abstract/Free Full Text]
  27. Costes SV, Daelemans D, Cho EH, et al. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J 2004;86:3993–4003.[CrossRef][Medline]
  28. Copeland NG, Zelenetz AD, Cooper GM. Transformation of NIH/3T3 mouse cells by DNA of Rous sarcoma virus. Cell 1979;17:993–1002.[CrossRef][Medline]
  29. Keller P, Simons K. Cholesterol is required for surface transport of influenza virus hemagglutinin. J Cell Biol 1998;140:1357–67.[Abstract/Free Full Text]
  30. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 2007;27:267–82.[Abstract/Free Full Text]
  31. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002;122:1493–9.[CrossRef][Medline]
  32. Isozaki K, Terris B, Belghiti J, et al. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157:1581–5.[Abstract/Free Full Text]
  33. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19:323–4.[CrossRef][Medline]
  34. Rubin BP, Antonescu CR, Scott-Browne JP, et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 2005;65:6631–9.[Abstract/Free Full Text]
  35. Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A 2003;100:6706–11.[Abstract/Free Full Text]
  36. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, et al. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 1991;10:4121–8.[Medline]
  37. Koshimizu U, Tsujimura T, Isozaki K, et al. Wn mutation of c-kit receptor affects its post-translational processing and extracellular expression. Oncogene 1994;9:157–62.[Medline]
  38. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:3999–4006.[CrossRef][Medline]
  39. Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E. PDGFR{alpha}- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 2005;46:166–75.[CrossRef][Medline]
  40. Jahn T, Seipel P, Coutinho S, et al. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene 2002;21:4508–20.[CrossRef][Medline]
  41. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736–44.[Medline]
  42. Vanderwinden JM, Wang D, Paternotte N, et al. Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT. Cell Signal 2006;18:661–9.[CrossRef][Medline]
  43. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 2003;22:4710–22.[CrossRef][Medline]
  44. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270–9.[CrossRef][Medline]
  45. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002;21:3314–33.[CrossRef][Medline]
  46. Roussel MF, Downing JR, Rettenmier CW, Sherr CJ. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell 1988;55:979–88.[CrossRef][Medline]
  47. Schmidt-Arras DE, Bohmer A, Markova B, et al. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol 2005;25:3690–703.[Abstract/Free Full Text]
  48. Theou-Anton N, Tabone S, Brouty-Boye D, et al. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 2006;94:1180–5.[CrossRef][Medline]
  49. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004;64:5355–62.[Abstract/Free Full Text]
  50. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004;10:6487–501.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tabone-Eglinger, S.
Right arrow Articles by Emile, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabone-Eglinger, S.
Right arrow Articles by Emile, J.-F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online